Federal grants and Genentech paid for the study, and Gilbert consults for the company.
This synthetic protein, licensed from Genentech, can help these kids grow and reduce such long-term complications.
That company, Genentech, is now the biggest seller of targeted cancer treatments in the world.
Henner knew about a growth hormone discovered at Genentech but not fully developed into a drug.
But Genentech is certain to dominate May's annual meeting of the American Society for Clinical Oncology.
The new Roche drug, being developed by its Genentech unit, inhibits a molecule called PD-L1.
The main competition is not another company's drug but low doses of Genentech's cancer fighter Avastin.
Since Genentech first announced its success with Lucentis two months ago, Eyetech shares have plummeted.
It appears to restore the effectiveness of Genentech 's Herceptin drug after that drug has failed.
But that isn't all Genentech had to offer cancer doctors at the ASCO conference.
Over the past year, Serono shares have done better than those of Amgen or Genentech.
Genentech has a reputation as being more focused on science than most of its peers.
FedEx, Southwest Airlines, Microsoft, Apple, Genentech, Oracle and others were born in the 1970s.
Bernstein or its affiliates have investment discretion over more than 1% of Genentech's stock.
Porges thinks all the value is already priced in, and rates Genentech stock market perform.
That same year Herb Boyer and Bob Swanson incorporated Genentech and launched the biotechnology revolution.
Its drug fights psoriasis, but Biogen, Amgen and Genentech won't quietly get out of the way.
Genentech's Avastin was once seen as one of the most promising cancer fighters around.
Genentech's breast cancer drug Herceptin works only in women whose cancer has a particular mutated gene.
Genentech is buoyed by preliminary results of a small lung-cancer trial conducted by M.
Genentech is still planning a big trial of Avastin in front-line ovarian cancer, Porges said.
He owns shares of Genentech, but his company does not do banking for the biotech.
But in 1990 Genentech decided to focus on other protein drugs and canceled Patton's research project.
Genentech's legal battle reveals another risk: Biotechnology companies are often formed around work done at universities.
But investors might want to be careful about extrapolating too much from Genentech's legal battles.
If Genentech doesn't win on appeal, they say, it can easily withstand a massive one-time charge.
In other words, Genentech made a mistake in which clinical trials it chose to do.
"Many people fly by the seat of their pants in science, " says Genentech pathologist Kenneth Hillan.
Just a week ago, doubts were swirling around several of Genentech 's experimental drugs.
"We'll be taking that charge in this quarter, " says Genentech Chief Financial Officer Louis J.
应用推荐